Ad
ADVM - Adverum Biotechnologies Stock Trading
About | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
Not available
Quote | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
| Last: | $0.923 |
|---|---|
| Change Percent: | 0.23% |
| Open: | $0.883 |
| Close: | $0.923 |
| High: | $0.945 |
| Low: | $0.83 |
| Volume: | 181,099 |
| Last Trade Date Time: | 12/06/2023 03:00:00 am |
News | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
-
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and St...
-
2023-11-09 17:51:02 ET More on Adverum Biotechnologies Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy Adverum Biotechnologies appoints Andrew Ramelmeier as chief technology officer Seeking Alpha’s Quant Rating on Adverum Biotechnologies For fu...
Message Board Posts | Adverum Biotechnologies Inc. (NASDAQ:ADVM)
| Subject | By | Source | When |
|---|---|---|---|
| $ADVM: Watching here at 0.70 now............ readytogooooooo | makinezmoney | investorshub | 01/30/2023 3:01:27 PM |
| Adverum lays off 78 employees, bets it all | conix | investorshub | 07/08/2022 2:49:25 PM |
| News but PPS not active premarket. | kzivann | investorshub | 01/04/2022 1:26:50 PM |
| $ADVM chart on the mend | conix | investorshub | 08/26/2021 12:54:36 PM |
| Form 4 - options granted for newly hired | TraderNeoMtl | investorshub | 06/04/2021 1:37:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
Ad
-
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to estab...
-
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and St...
-
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating th...